VEC.L Share News (VEC)

VEC.L Information

There is currently no data for VEC

Breezhaler better than Seretide, says Vectura

Mon, 05th Sep 2016 07:42

(ShareCast News) - Inhaled airways disease focused pharmaceuticals company Vectura Group confirmed an announcement from its alliance partner Novartis on Monday, that new analyses from the head-to-head FLAME study confirmed that Ultibro Breezhaler is a "more effective option" for patients at risk of chronic obstructive pulmonary disease flare-ups than Seretide.The FTSE 250 firm said the finding was true across different patient sub-groups.In the new analyses, once-daily Ultibro Breezhaler 110/50 mcg demonstrated consistent reductions in the rate of all exacerbations, regardless of age, smoking status, exacerbation history, disease severity, eosinophil levels and previous inhaled corticosteroid use, versus twice-daily Seretide 50/500 mcg."Specifically, among patients with the severest forms of COPD, Ultibro Breezhaler significantly reduced the rate of exacerbations and improved their health status versus the commonly used ICS/LABA combination," Vectura's board said in the statement."In addition, patients using Ultibro Breezhaler needed less rescue medication during the day."It added that new analyses presented at ERS 2016 also showed that, compared to Seretide, Ultibro Breezhaler was associated with fewer systemic effects, namely impairment of adrenal function, which regulates the natural production of hormones."Ultibro Breezhaler use has previously shown to be associated with significantly fewer cases of pneumonia than the ICS/LABA combination."Vectura said Novartis is presenting over 35 abstracts from across its broad respiratory portfolio at ERS 2016."These new findings further demonstrate the superior efficacy of Ultibro Breezhaler versus Seretide across a range of patient sub-groups and support its use as a steroid-free treatment option for COPD patients at risk of exacerbations," explained Vectura CEO James Ward-Lilley."This, combined with the existing efficacy and safety profile of Ultibro Breezhaler, further confirms our confidence in its outlook."

More News

25 Jan 2017 07:48

Vectura sales trigger $5m milestone receipt

(ShareCast News) - Vectura said on Wednesday that a sales milestone receipt of $5m has been triggered following confirmation by Novartis that EU/Rest of World combined net sales of its Seebri Breezhaler and Ultibro Breezhaler for the year to the end of December have reached $512m. The milestone will

24 Jan 2017 08:21

Vectura gets FDA investigational approval for VR647

(ShareCast News) - Device and formulation business for inhaled airways disease, Vectura Group, announced on Tuesday it has received an 'Investigational New Drug' approval from the US Food and Drug Administration for its VR647 product. The FTSE 250 firm said the approval will allow it to conduct a Ph

24 Jan 2017 07:47

Vectura Gets US Approval For Phase I Trial Of Asthma Treatment

11 Jan 2017 08:25

Vectura makes 'significant progess' in third quarter

(ShareCast News) - Inhaled airways disease device and formulation business Vectura Group announced an unaudited pre-close update on Wednesday, ahead of its results for the nine months to 31 December, due in March. The FTSE 250 company said that following the step-change in financial performance anno

11 Jan 2017 07:58

Respiratory Medicine-Maker Vectura Breathing Easy Over Revenue Targets

23 Dec 2016 10:03

WINNERS & LOSERS SUMMARY: PayPoint Sale And Special Payout Lift Shares

23 Dec 2016 07:57

Vectura Group signs development agreement with Mundipharma

(ShareCast News) - Inhaled airways disease device and formulation business Vectura Group announced on Friday that it has signed a development and licence agreement with Mundipharma International Corporation and a US independent associated company as the global development and commercialisation partn

22 Dec 2016 14:57

Vectura says Bayer completes EU approval procedure for alternative nebulised delivery

(ShareCast News) - Vectura said on Thursday that its partner Bayer has confirmed completion of the EU regulatory procedure that allows an alternative nebulised delivery for its currently-marketed product Ventavis using the London-listed company's smart nebuliser Fox device. Ventavis has been develop

21 Dec 2016 14:15

Vectura says Novartis signs US licensing agreement for COPD treatments

(ShareCast News) - Vectura announced that Swiss pharmaceutical company Novartis has signed a licensing agreement with Sunovion Pharmaceuticals for the US commercialisation rights to three treatments for chronic obstructive pulmonary disease for which it receives royalty revenues. Novartis, whose pro

8 Dec 2016 07:57

Vectura confirms positive study results for Ultibro Breezhaler

(ShareCast News) - Inhaled airways disease-focused business Vectura Group confirmed an announcement by its partner Novartis on Thursday. The FTSE 250 firm said the announcement was of positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequ

23 Nov 2016 07:40

Vectura earnings surge as Skyepharma merger creates step-change

(ShareCast News) - Inhaler maker Vectura's interim revenue have soared following the merger with rival Skyepharma and a launch of new products. For the six months ended 30 September, revenue increased 183% to £73.9m, compared to the same period last year, primarily due to the completion of the £441m

22 Nov 2016 07:41

TOP NEWS: Hikma Signs Development And Licensing Deal With Vectura

20 Nov 2016 15:57

Sunday newspaper round-up: OBR, Saudi Aramco, Tesco, BAT, bonds vigilantes

(ShareCast News) - The Office for Budget Responsibility is likely to cut its forecast for UK growth next year by the biggest margin since the peak of the eurozone debt crisis. Philip Hammond's Autumn Statement this week will see the Chancellor set out his multi-billion pound infrastructure plans and

17 Nov 2016 17:10

LONDON MARKET CLOSE: Strong US Data, Yellen Comments Point To Fed Hike

26 Oct 2016 14:14

Vectura climbs on positive read-across from Novartis, Singer upgrade

(ShareCast News) - Shares in medical device group Vectura were given a boost by expectations of foreign currency gains and investors reading across results from Novartis, with which the London-listed company is partnered on a handful of products. A third-quarter update from Novartis on Tuesday in

Latest Share Chat

VEC.L Share News (VEC)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Breezhaler better than Seretide, says Vectura

Login to your account

Quickpicks are a member only feature

Login to your account